Epigenetic aspects of MDS and its molecular targeted therapy (Q38051195)

27 August 2017

title

Epigenetic aspects of MDS and its molecular targeted therapy (English)

1 reference

27 August 2017

Jean-Pierre J Issa

0 references

Jumpei Yamazaki

1 reference

27 August 2017

publication date

10 October 2012

1 reference

International Journal of Hematology

27 August 2017

published in

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

175-182

1 reference

The epigenomics of cancer

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Cancer epigenetics comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Genomic DNA methylation: the mark and its mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

CpG islands--'a rough guide'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

X-chromosome inactivation in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Gametic imprinting in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Genomic imprinting: the emergence of an epigenetic paradigm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Relationships between chromatin organization and DNA methylation in determining gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

The nucleosome: from genomic organization to genomic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

The many faces of histone lysine methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Histone methylation versus histone acetylation: new insights into epigenetic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Hypomethylation distinguishes genes of some human cancers from their normal counterparts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Hypomethylation: One Side of a Larger Picture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

DNA hypomethylation leads to elevated mutation rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Epigenetic changes in the myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Epigenetic stem cell signature in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

MLL-rearranged leukemias: insights from gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Epigenetic changes in therapy-related MDS/AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

CpG island methylator phenotype in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Mutations in epigenetic regulators in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Targeting DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Unraveling the molecular pathophysiology of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1197-4

Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation

21 January 2018

1 reference

12 December 2020

Reduced genomic 5-methylcytosine content in human colonic neoplasia

1 reference

12 December 2020

Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression

1 reference

12 December 2020

Methylation status of LINE-1 sequences in patients with MDS or secondary AML

1 reference

12 December 2020

Alterations in DNA methylation: a fundamental aspect of neoplasia

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S12185-012-1197-4

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1039511024

0 references

1 reference